Johan van Griensven1, Tansy Edwards, Xavier de Lamballerie, Malcolm G Semple, Pierre Gallian, Sylvain Baize, Peter W Horby, Hervé Raoul, N'Faly Magassouba, Annick Antierens, Carolyn Lomas, Ousmane Faye, Amadou A Sall, Katrien Fransen, Jozefien Buyze, Raffaella Ravinetto, Pierre Tiberghien, Yves Claeys, Maaike De Crop, Lutgarde Lynen, Elhadj Ibrahima Bah, Peter G Smith, Alexandre Delamou, Anja De Weggheleire, Nyankoye Haba. 1. From the Institute of Tropical Medicine, Antwerp (J.G., K.F., J.B., R.R., Y.C., M.D.C., L.L., A.D.W.), Médecins sans Frontières, Brussels (A.A., C.L.), and the Clinical Pharmacology and Pharmacotherapy Department, Katholieke Universiteit Leuven, Leuven (R.R.) - all in Belgium; Medical Research Council Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London (T.E., P.G.S.), Institute of Translational Medicine and National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool (M.G.S.), and Centre for Tropical Medicine and Global Health, University of Oxford, Oxford (P.W.H.) - all in the United Kingdom; Aix Marseille University (X.L., P.G.), French Institute of Research for Development (X.L.), École des Hautes Études en Santé Publique (X.L.), and Institut Hospitalo-Universitaire Méditerranée Infection (X.L., P.G.), Marseille, Etablissement Français du Sang, La Plaine Saint Denis (P.G., P.T.), Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (S.B.), Laboratoire P4 INSERM-Jean Mérieux (H.R.), Lyon, and Université de Franche Comté, Etablissement Français du Sang, INSERM UMR 1098, Besançon (P.T.) - all in France; Laboratory of Viral Hemorrhagic Fever, Gamal Abdel Nasser University of Conakry (N.M.), Service des Maladies Infectieuses et Tropicales de l'Hôpital National Donka, Conakry (E.I.B.), National Blood Transfusion Center (N.H.), Conakry, and National Center for Training and Research in Rural Health of Maferinyah, Forecariah (A.D.) - all in Guinea; and Institut Pasteur de Dakar, Dakar, Senegal (O.F., A.A.S.).
Abstract
BACKGROUND: In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. METHODS: In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. RESULTS: A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. CONCLUSIONS: The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.).
BACKGROUND: In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. METHODS: In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. RESULTS: A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. CONCLUSIONS: The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.).
Authors: Marta Mora-Rillo; Marta Arsuaga; Germán Ramírez-Olivencia; Fernando de la Calle; Alberto M Borobia; Paz Sánchez-Seco; Mar Lago; Juan C Figueira; Belén Fernández-Puntero; Aurora Viejo; Anabel Negredo; Concepción Nuñez; Eva Flores; Antonio J Carcas; Victor Jiménez-Yuste; Fátima Lasala; Abelardo García-de-Lorenzo; Francisco Arnalich; Jose R Arribas Journal: Lancet Respir Med Date: 2015-05-31 Impact factor: 30.700
Authors: Elhadj Ibrahima Bah; Marie-Claire Lamah; Tom Fletcher; Shevin T Jacob; David M Brett-Major; Amadou Alpha Sall; Nahoko Shindo; William A Fischer; Francois Lamontagne; Sow Mamadou Saliou; Daniel G Bausch; Barry Moumié; Tim Jagatic; Armand Sprecher; James V Lawler; Thierry Mayet; Frederique A Jacquerioz; María F Méndez Baggi; Constanza Vallenas; Christophe Clement; Simon Mardel; Ousmane Faye; Oumar Faye; Baré Soropogui; Nfaly Magassouba; Lamine Koivogui; Ruxandra Pinto; Robert A Fowler Journal: N Engl J Med Date: 2014-11-05 Impact factor: 91.245
Authors: John M Dye; Andrew S Herbert; Ana I Kuehne; James F Barth; Majidat A Muhammad; Samantha E Zak; Ramon A Ortiz; Laura I Prugar; William D Pratt Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: John S Schieffelin; Jeffrey G Shaffer; Augustine Goba; Michael Gbakie; Stephen K Gire; Andres Colubri; Rachel S G Sealfon; Lansana Kanneh; Alex Moigboi; Mambu Momoh; Mohammed Fullah; Lina M Moses; Bethany L Brown; Kristian G Andersen; Sarah Winnicki; Stephen F Schaffner; Daniel J Park; Nathan L Yozwiak; Pan-Pan Jiang; David Kargbo; Simbirie Jalloh; Mbalu Fonnie; Vandi Sinnah; Issa French; Alice Kovoma; Fatima K Kamara; Veronica Tucker; Edwin Konuwa; Josephine Sellu; Ibrahim Mustapha; Momoh Foday; Mohamed Yillah; Franklyn Kanneh; Sidiki Saffa; James L B Massally; Matt L Boisen; Luis M Branco; Mohamed A Vandi; Donald S Grant; Christian Happi; Sahr M Gevao; Thomas E Fletcher; Robert A Fowler; Daniel G Bausch; Pardis C Sabeti; S Humarr Khan; Robert F Garry Journal: N Engl J Med Date: 2014-10-29 Impact factor: 91.245
Authors: K Mupapa; W Mukundu; M A Bwaka; M Kipasa; A De Roo; K Kuvula; K Kibadi; M Massamba; D Ndaberey; R Colebunders; J J Muyembe-Tamfum Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226
Authors: Junerlyn Agua-Agum; Archchun Ariyarajah; Isobel M Blake; Anne Cori; Christl A Donnelly; Ilaria Dorigatti; Christopher Dye; Tim Eckmanns; Neil M Ferguson; Robert A Fowler; Christophe Fraser; Tini Garske; Wes Hinsley; Thibaut Jombart; Harriet L Mills; Srinivas Murthy; Gemma Nedjati Gilani; Pierre Nouvellet; Louise Pelletier; Steven Riley; Dirk Schumacher; Anita Shah; Maria D Van Kerkhove Journal: N Engl J Med Date: 2015-03-26 Impact factor: 91.245
Authors: John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck Journal: J Infect Dis Date: 2014-07-16 Impact factor: 5.226
Authors: Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger Journal: Nature Date: 2014-08-29 Impact factor: 49.962
Authors: Jerry F Brown; Kathleen Rowe; Peter Zacharias; James van Hasselt; John M Dye; David A Wohl; William A Fischer; Coleen K Cunningham; Nathan M Thielman; David L Hoover Journal: J Clin Apher Date: 2016-07-08 Impact factor: 2.821
Authors: Joel G Breman; David L Heymann; Graham Lloyd; Joseph B McCormick; Malonga Miatudila; Frederick A Murphy; Jean-Jacques Muyembé-Tamfun; Peter Piot; Jean-François Ruppol; Pierre Sureau; Guido van der Groen; Karl M Johnson Journal: J Infect Dis Date: 2016-06-29 Impact factor: 5.226
Authors: Jerry F Brown; John M Dye; Sam Tozay; Gertrude Jeh-Mulbah; David A Wohl; William A Fischer; Coleen K Cunningham; Kathleen Rowe; Peter Zacharias; James van Hasselt; David A Norwood; Nathan M Thielman; Samantha E Zak; David L Hoover Journal: J Infect Dis Date: 2018-07-13 Impact factor: 5.226
Authors: Richard T Davey; Lori Dodd; Michael A Proschan; James Neaton; Jacquie Neuhaus Nordwall; Joseph S Koopmeiners; John Beigel; John Tierney; H Clifford Lane; Anthony S Fauci; Moses B F Massaquoi; Foday Sahr; Denis Malvy Journal: N Engl J Med Date: 2016-10-13 Impact factor: 91.245
Authors: Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu Journal: Trends Mol Med Date: 2017-08-17 Impact factor: 11.951
Authors: M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco Journal: Annu Rev Virol Date: 2016-08-15 Impact factor: 10.431